Corsi F - Search Results

1

Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.

Di Modica M, Gargari G, Regondi V, Bonizzi A, Arioli S, Belmonte B, De Cecco L, Fasano E, Bianchi F, Bertolotti A, Tripodo C, Villani L, Corsi F, Guglielmetti S, Balsari A, Triulzi T, Tagliabue E. Di Modica M, et al. Among authors: corsi f. Cancer Res. 2021 Apr 15;81(8):2195-2206. doi: 10.1158/0008-5472.CAN-20-1659. Epub 2021 Jan 22. Cancer Res. 2021. PMID: 33483370 Free article.

2

HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.

Colombo M, Corsi F, Foschi D, Mazzantini E, Mazzucchelli S, Morasso C, Occhipinti E, Polito L, Prosperi D, Ronchi S, Verderio P. Colombo M, et al. Among authors: corsi f. Pharmacol Res. 2010 Aug;62(2):150-65. doi: 10.1016/j.phrs.2010.01.013. Epub 2010 Feb 1. Pharmacol Res. 2010. PMID: 20117211 Review.

3

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. De Mattos-Arruda L, et al. Among authors: corsi f. Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495. Oncotarget. 2015. PMID: 26452030 Free PMC article.

4

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.

Truffi M, Colombo M, Sorrentino L, Pandolfi L, Mazzucchelli S, Pappalardo F, Pacini C, Allevi R, Bonizzi A, Corsi F, Prosperi D. Truffi M, et al. Among authors: corsi f. Sci Rep. 2018 Apr 26;8(1):6563. doi: 10.1038/s41598-018-24968-x. Sci Rep. 2018. PMID: 29700387 Free PMC article.

5

Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.

Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S. Colombo M, et al. Among authors: corsi f. Bioconjug Chem. 2018 Nov 21;29(11):3817-3832. doi: 10.1021/acs.bioconjchem.8b00667. Epub 2018 Oct 25. Bioconjug Chem. 2018. PMID: 30350574

6

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy.

Truffi M, Mazzucchelli S, Bonizzi A, Sorrentino L, Allevi R, Vanna R, Morasso C, Corsi F. Truffi M, et al. Among authors: corsi f. Int J Mol Sci. 2019 Mar 13;20(6):1263. doi: 10.3390/ijms20061263. Int J Mol Sci. 2019. PMID: 30871158 Free PMC article. Review.

7

Radio-guided and clip-guided preoperative localization for malignant microcalcifications offer similar performances in breast-conserving surgery.

Corsi F, Bossi D, Sartani A, Papadopoulou O, Amadori R, Scoccia E, Trifirò G, Albasini S, Truffi M, Bonizzi A, Sorrentino L. Corsi F, et al. Breast J. 2019 Sep;25(5):865-873. doi: 10.1111/tbj.13354. Epub 2019 Jun 11. Breast J. 2019. PMID: 31187568

8

Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer.

Mazzucchelli S, Piccotti F, Allevi R, Truffi M, Sorrentino L, Russo L, Agozzino M, Signati L, Bonizzi A, Villani L, Corsi F. Mazzucchelli S, et al. Among authors: corsi f. Biol Proced Online. 2019 Jun 15;21:12. doi: 10.1186/s12575-019-0099-8. eCollection 2019. Biol Proced Online. 2019. PMID: 31223292 Free PMC article.

9

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines.

Bonizzi A, Truffi M, Sevieri M, Allevi R, Sitia L, Ottria R, Sorrentino L, Sottani C, Negri S, Grignani E, Mazzucchelli S, Corsi F. Bonizzi A, et al. Among authors: corsi f. Pharmaceutics. 2019 Aug 2;11(8):384. doi: 10.3390/pharmaceutics11080384. Pharmaceutics. 2019. PMID: 31382388 Free PMC article.

10

Involved margins after lumpectomy for breast cancer: Always to be re-excised?

Sorrentino L, Agozzino M, Albasini S, Bossi D, Mazzucchelli S, Vanna R, Papadopoulou O, Villani L, Corsi F. Sorrentino L, et al. Among authors: corsi f. Surg Oncol. 2019 Sep;30:141-146. doi: 10.1016/j.suronc.2019.08.002. Epub 2019 Aug 6. Surg Oncol. 2019. PMID: 31500779 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

258 results

Search Page